ReviewCancers2020
Neoadjuvant Systemic Treatment of Primary Angiosarcoma.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Clinical and prognostic insights into radiation-associated angiosarcoma: a multi-institutional analysis.Radiation oncology (London, England) · 2026Article
- Prognostic significance of clinicopathological parameters, margin width and locoregional recurrences on outcome of primary and radiation associated breast angiosarcoma- results from a large UK sarcoma regional service.Breast cancer research : BCR · 2026Article
- Primary cardiac angiosarcoma with isolated superior vena cava syndrome: a case report.Journal of medical case reports · 2026Article
- Multimodal Therapy in Cutaneous Angiosarcoma: A National Cancer Database Study of Treatment Patterns and Survival.Annals of surgical oncology · 2026Article
- Article
- Primary Jejunal Angiosarcoma.ACG case reports journal · 2025Article
- An FDA-approved drug library screening identifies proteasome inhibitors as selective cytotoxic agents for angiosarcoma cells.British journal of cancer · 2025Review
- Complete remission in a rare pelvic angiosarcoma with liposomal doxorubicin: A comprehensive case report and review of literature.Rare tumors · 2025Article
- Article
- Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma.Genes, chromosomes & cancer · 2024Article
- Current understanding of angiosarcoma: disease biology and evolving treatment.Archives of craniofacial surgery · 2023Article
- Article
- Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans.Frontiers in oncology · 2023Review
- PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report.Medicine · 2022Article
- Management of Cutaneous Angiosarcoma: an Update Review.Current treatment options in oncology · 2022Review
- New nomograms to predict overall and cancer-specific survival of angiosarcoma.Cancer medicine · 2022Article
- Epigenetics of Cutaneous Sarcoma.International journal of molecular sciences · 2021Review
- Article
- Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology.Biomedicines · 2021Review
- Current Management of Angiosarcoma: Recent Advances and Lessons From the Past.Current treatment options in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcoma is an extremely rare and aggressive malignancy. Standard of care of localized tumors includes surgery ± radiation. Despite this multimodal treatment, >50% of the angiosarcoma patients develop local or distant recurrent disease. The role of neoadjuvant systemic therapy is still controversial and we therefore performed a systematic review of the literature to define the role of neoadjuvant systemic therapy based on available evidence. We focused on the effects of neoadjuvant systemic therapy on: 1. The success of surgical resection and 2. the long-term survival. All articles published before October 2019 on Ovid Medline, Ovid Embase, Cochrane library and Scopus were evaluated. Eighteen case reports and six retrospective cohort studies were included. There were no randomized controlled trials. This literature showed a beneficial role of neoadjuvant chemotherapy on downsizing of the tumor resulting in an improvement of the resection margins, especially in patients with cardiac or cutaneous angiosarcoma. However, no definitive conclusions on survival can be drawn based on the available literature lacking any prospective randomized studies in this setting. We advise that neoadjuvant chemotherapy should be considered, since this could lead to less mutilating resections and a higher rate of free resection margins. An international angiosarcoma registry could help to develop guidelines for this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.